GSK’s linerixibat helped reduce itch in patients with a rare bile duct disease, meeting its primary endpoint in a late-stage ...

The FDA has denied Astellas’ attempt to bolster the label for its vision loss treatment Izervay with additional two-year data ...

Tianjin Darentang Jingwanhong Pharmaceutical received an FDA warning letter for concealing manufacturing information, ...

The UK's drug pricing body has affirmed its earlier decision not to recommend coverage of AstraZeneca and Daiichi Sankyo’s ...

Eli Lilly's oral drug muvalaplin showed significant reductions in lipoprotein(a) levels in a Phase 2 trial of 233 high-risk ...

Efforts by the pharmaceutical industry to expand access to low-and-middle-income countries need to be “vastly accelerated” ...

T cell therapy for autoimmune diseases, showing clinical responses in seven lupus patients. The therapy uses the same ...

Johnson & Johnson and Protagonist Therapeutics announced two Phase 3 successes for their oral IL-23 drug, showcasing the ...

BeiGene has settled a lawsuit with generics manufacturer MSN Pharmaceuticals, resolving all cases associated with the entry ...

They've got $70 million, two guys named Ned, and plans to go after early-stage science where other venture capital firms ...

Merck's subcutaneous version of Keytruda succeeded in Phase 3 trials, showing non-inferior results to its IV counterpart. The ...

Incyte’s $750 million buyout of Escient Pharmaceuticals is in a rough patch as a mid-stage chronic hives candidate was ...